These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

900 related items for PubMed ID: 16339666

  • 41. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
    Chunduri S, Dobogai LC, Peace D, Saunthararajah Y, Quigley J, Chen YH, Mahmud N, Hurter E, Beri R, Rondelli D.
    Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
    [Abstract] [Full Text] [Related]

  • 42. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH, Huang XJ, Liu KY, Xu LP, Liu DH, Chen H, Chen YH, Wang JZ, Han W, Lu DP.
    Chin Med J (Engl); 2007 Mar 20; 120(6):463-8. PubMed ID: 17439737
    [Abstract] [Full Text] [Related]

  • 43. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ, Li J, Tan EX, Zhang GC, Wu XY, Peng AH, Zheng D, Zou WY, Hong WD, Luo SK.
    Zhonghua Zhong Liu Za Zhi; 2006 Jul 20; 28(7):545-8. PubMed ID: 17147125
    [Abstract] [Full Text] [Related]

  • 44. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F, Lang PJ, Ottinger H, Faul C, Bethge W, Handgretinger R, Bamberg M, Belka C.
    Int J Radiat Oncol Biol Phys; 2008 Feb 01; 70(2):523-8. PubMed ID: 17869449
    [Abstract] [Full Text] [Related]

  • 45. Comparison of peripheral blood stem cell transplant with bone marrow transplant in class 3 thalassemic patients.
    Iravani M, Tavakoli E, Babaie MH, Ashouri A, Khatami F, Ghavamzadeh A.
    Exp Clin Transplant; 2010 Mar 01; 8(1):66-73. PubMed ID: 20199374
    [Abstract] [Full Text] [Related]

  • 46. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.
    List AF, Maziarz R, Stiff P, Jansen J, Liesveld J, Andrews F, Schuster M, Wolff S, Litzow M, Karanes C, Dahlberg S, Kirkhart B, Bianco JA, Singer JW.
    Bone Marrow Transplant; 2000 Feb 01; 25(3):283-91. PubMed ID: 10673700
    [Abstract] [Full Text] [Related]

  • 47. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research.
    Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giralt S, Molina A, Copelan EA, Ringdén O, Roy V, Ballen K, Adkins DR, McCarthy P, Weisdorf D, Montserrat E, Anasetti C.
    J Clin Oncol; 2005 Aug 20; 23(24):5788-94. PubMed ID: 16043827
    [Abstract] [Full Text] [Related]

  • 48. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T, Taniguchi Y, Hasei H, Kaida K, Inoue T, Kim EH, Kawase I.
    Biol Blood Marrow Transplant; 2006 Oct 20; 12(10):1073-84. PubMed ID: 17084371
    [Abstract] [Full Text] [Related]

  • 49. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH, Zhang C, Zhang X, Gao L, Gao L, Kong PY, Peng XG, Qi DG, Sun AH, Zeng DF, Liu H, Gong Y, Wang QY.
    Biol Blood Marrow Transplant; 2009 Feb 20; 15(2):266-73. PubMed ID: 19167687
    [Abstract] [Full Text] [Related]

  • 50. Bone marrow transplantation in thalassemia.
    Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Durazzi SM, Giardini C, Nicolini G, Politi P, Albertini F.
    Hematol Oncol Clin North Am; 1991 Jun 20; 5(3):549-56. PubMed ID: 1864822
    [Abstract] [Full Text] [Related]

  • 51. Unexpected complications after bone marrow transplantation in transfusion-dependent children.
    Saunders EF, Olivieri N, Freedman MH.
    Bone Marrow Transplant; 1993 Jun 20; 12 Suppl 1():88-90. PubMed ID: 8374573
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning.
    Martino R, Pérez-Simón JA, Moreno E, Queraltó JM, Caballero D, Mateos M, Sureda A, Cañizo C, Brunet S, Briones J, Vazquez L, Clopés A, San Miguel JF, Sierra J.
    Biol Blood Marrow Transplant; 2005 Jun 20; 11(6):437-47. PubMed ID: 15931632
    [Abstract] [Full Text] [Related]

  • 54. Progress in hematopoietic stem cell transplantation as allogeneic cellular gene therapy in thalassemia.
    Isgrò A, Gaziev J, Sodani P, Lucarelli G.
    Ann N Y Acad Sci; 2010 Aug 20; 1202():149-54. PubMed ID: 20712786
    [Abstract] [Full Text] [Related]

  • 55. The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases.
    Rosales F, Peylan-Ramu N, Cividalli G, Varadi G, Or R, Naparstek E, Slavin S, Nagler A.
    Bone Marrow Transplant; 1999 May 20; 23(9):861-5. PubMed ID: 10338039
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study.
    Yakoub-Agha I, Fawaz A, Folliot O, Guillerm G, Quesnel B, Fenaux P, Bauters F, Jouet JP, Morschhauser F.
    Bone Marrow Transplant; 2002 Aug 20; 30(4):229-34. PubMed ID: 12203139
    [Abstract] [Full Text] [Related]

  • 58. Bone marrow transplantation for thalassaemia.
    Lucarelli G.
    J Intern Med Suppl; 1997 Aug 20; 740():49-52. PubMed ID: 9350182
    [Abstract] [Full Text] [Related]

  • 59. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, Lee S, Cho SG, Jin JY, Lee JW, Kim CC.
    Biol Blood Marrow Transplant; 2009 Jun 20; 15(6):704-17. PubMed ID: 19450755
    [Abstract] [Full Text] [Related]

  • 60. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.
    Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kozak T, Havrdova E, Carreras E, Graus F, Kashyap A, Openshaw H, Schipperus M, Deconinck E, Mancardi G, Marmont A, Hansz J, Rabusin M, Zuazu Nagore FJ, Besalduch J, Dentamaro T, Fouillard L, Hertenstein B, La Nasa G, Musso M, Papineschi F, Rowe JM, Saccardi R, Steck A, Kappos L, Gratwohl A, Tyndall A, Samijn J, Autoimmune Disease Working Party of the EBMT (European Group for Blood and Marrow Transplantation).
    J Neurol; 2002 Aug 20; 249(8):1088-97. PubMed ID: 12195460
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 45.